Navigation Links
Internal Fixation Systems Announces 510(k) Approval Granted by FDA for Subtalar Implants
Date:1/23/2012

MIAMI, Jan. 23, 2012 /PRNewswire/ -- (OTC: IFIX) Internal Fixation Systems today announced that it has received 510(k) clearance from the FDA to market subtalar implants. These implants are used to preserve motion at the ankle joint and to treat both trauma conditions and arthritis.  IFS CEO, Stephen Dresnick, MD, stated that, "this approval allows us to continue to fill out our portfolio, and gives us another product for surgeons who use our products." IFS currently offers a full line of mini-cannulated screws for small bone fixation as well as a Modular Locking Small Fragment System for treatment of bone fractures and osteotomies. 

About IFS:  Internal Fixation Systems, Inc is a manufacturer and marketer of high quality, responsibly priced orthopedic and podiatric implants.
We seek to prove that superior products and lower costs can go hand in hand.   IFS focuses on widely used, market proven products used to treat common fractures.  Our Advisory Panel, consisting of nationally recognized surgeons, provides input on how to improve our implant designs.  The resulting products incorporate doctor requested enhancements and are priced at 40-60% less than the competition.  IFS customers include ambulatory surgery centers, hospitals and orthopedic surgeons.  Please contact us for more information about our product and business model.
This press release contains projections and forward-looking information that involve various risks and uncertainties regarding future events.  Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of Internal Fixation, such as whether we sell our new product offering  There are numerous risks and uncertainties that could cause actual results and Internal Fixation's plans and objectives to differ materially from those expressed in the forward-looking information, including whether Internal Fixation will have sufficient capital to continue its operations..  Actual results and future events could differ materially from those anticipated in such information.  These and all subsequent written and oral forward-looking information are based on estimates and views of  management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, IFS does not intend to update these forward-looking statements.For further information, please contact:

Laura Cattabriga, Chief Financial Officer

  

Tel: 786 268 0995

  

Laura.cattabriga@ifsusa.net

 


'/>"/>

SOURCE Internal Fixation Systems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. JCM Passes Internal Quality Assessment for Azithromycin API Production
2. Internal and External Communication Insights: Effective Approaches for Reaching Clients and Co-Workers
3. Internal Fixation Systems, Inc. Announces Sale of Modular Locking Small Fragment System
4. Internal Fixation Systems, Inc. Announces DTC Eligibility
5. Internal Fixation Systems, Inc. Receives FDA 510(k) Clearance to Market Fixation Devices to Treat Bone Fractures and Osteotomies
6. Internal Groups are Valuable Sources for Pharmaceutical Competitive Intelligence Function
7. Building Support for a New Product Through Effective Internal Disease State Communication
8. Pharmaceutical Internal Communications Function Morphs to Address Corporate Priorities
9. Internal Fixation Systems, Inc. Announces Form S-1 Declared Effective by SEC and Anticipated Quotation for Trading on OTCQB
10. Maximizing the Potential of Internal and External Communications Groups
11. Johnson & Johnson Provides Update on McNeil Consumer Healthcare Remediation; Announces Completion of Internal Assessment Phase of Comprehensive Action Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... ZappRx, Inc ., a digital health company focused on modernizing ... closed $25 million in Series B funding led by Qiming ... Seattle that is part of a broader ... round included participation from SR One , who led ... (formerly Google Ventures). As part of the financing, Mark ...
(Date:4/20/2017)... April 20, 2017 Eyevensys, a ... first non-viral gene expression technology that enables the safe, ... to address a wide range of ophthalmic diseases, announces ... Healthcare products Regulatory Agency (MHRA) to advance its technology ... ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... 26, 2017 , ... Want to learn more about CRISPR-Cas ... that demonstrates how this advanced plant breeding technology is a more efficient way ... resources. It highlights the business’ principles, research and collaboration efforts in this area. ...
(Date:4/26/2017)... ... April 26, 2017 , ... MYOLYN, a medical ... that it has received 510(k) clearance from the U.S. Food & Drug Administration ... Pro. , Both devices are stationary cycling systems that use MYOLYN’s patent-pending ...
(Date:4/25/2017)... ... April 25, 2017 , ... ProRehab ... to be the preferred physical therapy provider for Derby City CrossFit, effective immediately. ... City CrossFit as quickly and effectively as possible, ProRehab’s sports physical therapists will ...
(Date:4/25/2017)... IN (PRWEB) , ... April 25, 2017 , ... ... D.C., CEOs, CFOs and HR decision-makers are preparing for how his administration could ... Financial will provide insight into what changes are most likely to make it ...
(Date:4/25/2017)... ... , ... Lake Park Dental is now accepting new patients with crooked teeth ... With the help of this highly-effective, yet convenient system, patients can straighten their teeth ... less pain. , Drs. Sarah Jockin, Nicole Morganti, Sara Spear and Elizabeth Dy, ...
Breaking Medicine News(10 mins):